newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Benzinga
Trial Data Show Improved Immune Response In Colorectal Cancer.
PDS01ADC achieved a 78% objective response rate versus 35% in colorectal cancer without it.
KEY POINTS
Treated patients had over 80% two-year survival, compared to 35% without PDS01ADC.
Median progression-free survival was not reached after 13.1 months with PDS01ADC.
PDS Biotechnology also reported early positive results for PDS01ADC in an NCI-led prostate cancer trial.
Trial Data Show Improved Immune Response In Colorectal Cancer
The published data from the trial indicate that PDS01ADC significantly enhances immune response in colorectal cancer patients who have failed prior treatments.
The stock’s rise follows the publication of findings showing a 78% objective response rate with PDS01ADC versus 35% in a parallel trial without PDS01ADC.
This promising result comes from a study that included 22 patients, with a two-year survival rate exceeding 80% for those treated with PDS01ADC versus 35%.
Progression-Free Survival Remains Unreached
The median progression-free survival (PFS) was not reached at the minimum follow-up of 13.1 months; in the parallel trial without PDS01ADC, the PFS was 8.1 months.
Additional Data From Prostate Cancer Study
Earlier, the company presented encouraging early results from an NCI-led trial investigating PDS01ADC at the AACR special conference on prostate cancer research.
PDSB Stock Price Activity: PDS Biotechnology shares were up 25.47% at $1.33 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by Aunt Spray via Shutterstock